"Receptor, ErbB-3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is specific for NEUREGULINS. It has extensive homology to and can heterodimerize with the EGF RECEPTOR and the ERBB-2 RECEPTOR. Overexpression of the erbB-3 receptor is associated with TUMORIGENESIS.
Descriptor ID |
D020893
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.009.500 D12.776.543.750.630.009.500 D12.776.543.750.750.400.074.500 D12.776.624.664.700.790 D23.101.140.721
|
Concept/Terms |
Receptor, ErbB-3- Receptor, ErbB-3
- ErbB-3 Receptor
- Receptor, ErbB 3
- Proto-Oncogene Protein erbB-3
- Proto Oncogene Protein erbB 3
- erbB-3, Proto-Oncogene Protein
- erbB-3 Protein
- erbB 3 Protein
- HER-3 Proto-Oncogene Protein
- HER 3 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-3
- Tyrosine Kinase-type Cell Surface Receptor HER3
- Tyrosine Kinase type Cell Surface Receptor HER3
- Proto-Oncogene Proteins erbB-3
- Proto Oncogene Proteins erbB 3
- erbB-3, Proto-Oncogene Proteins
- Proto-oncogene-like Protein c-ErbB-2
- Protein c-ErbB-2, Proto-oncogene-like
- Proto oncogene like Protein c ErbB 2
- c-ErbB-2, Proto-oncogene-like Protein
- c-erbB-3 Protein
- c erbB 3 Protein
- Proto-Oncogene Protein c-erbB-3
- Proto Oncogene Protein c erbB 3
- c-erbB-3, Proto-Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-3".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- ErbB Receptors [D08.811.913.696.620.682.725.400.009]
- Receptor, ErbB-3 [D08.811.913.696.620.682.725.400.009.500]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- ErbB Receptors [D12.776.543.750.630.009]
- Receptor, ErbB-3 [D12.776.543.750.630.009.500]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- ErbB Receptors [D12.776.543.750.750.400.074]
- Receptor, ErbB-3 [D12.776.543.750.750.400.074.500]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, ErbB-3 [D12.776.624.664.700.790]
- Biological Factors [D23]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Receptor, ErbB-3 [D23.101.140.721]
Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-3".
This graph shows the total number of publications written about "Receptor, ErbB-3" by people in this website by year, and whether "Receptor, ErbB-3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 2 | 0 | 2 |
2001 | 1 | 0 | 1 |
2011 | 0 | 1 | 1 |
2013 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2017 | 1 | 1 | 2 |
2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, ErbB-3" by people in Profiles.
-
Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling. Gastroenterology. 2025 Feb; 168(2):300-315.e3.
-
The phase I/II eNRGy trial: Zenocutuzumab in?patients with cancers harboring NRG1 gene fusions. Future Oncol. 2024; 20(16):1057-1067.
-
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies. J Thorac Oncol. 2024 01; 19(1):106-118.
-
Loci on chromosome 12q13.2 encompassing ERBB3, PA2G4 and RAB5B are associated with polycystic ovary syndrome. Gene. 2023 Feb 05; 852:147062.
-
A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations. Invest New Drugs. 2021 10; 39(5):1324-1334.
-
Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer. JCO Precis Oncol. 2021; 5.
-
NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors. Mol Cancer Ther. 2020 08; 19(8):1727-1735.
-
MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. Life Sci Alliance. 2020 06; 3(6).
-
ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis. Oncogene. 2020 04; 39(14):2921-2933.
-
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1409-1417.